Clinical Trials Browser

Phase 2 × Celecoxib × 30 days × Clear all

Colonic Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Rectal Neoplasms

NCT02574728 2026-03-02

AflacST1502

Phase 2 Active not recruiting

46 enrolled

CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

232 enrolled

CNS

Ependymoma, Medulloblastoma, Recurrence

Clinical Trials

NICHE

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

AflacST1502

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

MEMMAT